Now accepting Telehealth appointments. Schedule a virtual visit.

Dr Naheed Ali explains COVID 19 updated treatment guidelines


The COVID-19 Treatment Guidelines Panel is working tirelessly to ensure that doctors, providers, patients, researchers and and experts have most up to date data and information in terms of treating and managing COVID-19 in the best and safest possible way.

There is an expert panel who works on the new Guidelines and who updates and revise the existing Guidelines as needed from time to time. All recommendations in the Guidelines are endorsed by a majority of Panel members.

At present, current guidelines dictates that the Anti-SARS-CoV-2 monoclonal antibodies are available through Food and Drug Administration Emergency Use Authorizations (EUAs). Data changes and emerges on these monoclonal antibodies, including data from a Phase 3 trial of casirivimab plus imdevimab. After reviewing the available data, the Panel has updated its recommendations on the use of anti-SARS-CoV-2 monoclonal antibodies in outpatients with mild to moderate COVID-19 who are at high risk of disease progression.

The Panel recommends the following:

You Might Also Enjoy...